Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × NET × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2 Thoracic 1 Other hematologic neoplasm 1 NET 1 Myeloid 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 55 Gastro-enteropancreatic neuroendocrine tumor 11 Adenoma, Islet Cell 8 Breast Neoplasms 7 Prostatic Neoplasms 6 Carcinoma, Hepatocellular 6 Pancreatic Neoplasms 5 Neoplasm Metastasis 5 Melanoma 5 Colorectal Neoplasms 5 Carcinoma, Neuroendocrine 5 Thyroid Neoplasms 4 Stomach Neoplasms 4 Pheochromocytoma 4 Ovarian Neoplasms 4 Neoplasms 4 Brain Neoplasms 4 Thymus Neoplasms 3 Sarcoma 3 Rectal Neoplasms 3 Paraganglioma 3 Liver Neoplasms 3 Gallbladder Neoplasms 3 Esophageal Neoplasms 3 Colonic Neoplasms 3 Carcinoid Tumor 3 Bile Duct Neoplasms 3 Anus Neoplasms 3 Urinary Bladder Neoplasms 2 Testicular Neoplasms 2

Interventions

lutetium Lu 177 dotatate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04954820 2026-02-05

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting

Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡